“Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance”. Journal of Cancer Research Updates 2, no. 4 (November 28, 2013):  306–317. Accessed May 21, 2026. https://www.neoplasiaresearch.com/index.php/jcru/article/view/428.